The Effect of Hypertension Comorbidities on the Higher Income of Cardiovascular Disease Commorbides in Covid-19 Patients

Background: Covid-19 cases with cardiovascular comorbidities are associated with a high risk of morbidity and mortality in COVID-19 patients. Hypertension is one of the comorbidities found in people with COVID-19. In several studies, it was found that hypertension has the highest incidence rate in cases of COVID-19. Patients with cardiovascular comorbidities are more susceptible to SARS-CoV-2 infection and can experience more severe clinical manifestations presumably because it is associated with increased expression of ACE2, a functional coronavirus receptor that can bind to spike proteins on the viral surface directly. So that SARS-CoV-2 can enter host cells through the ACE2 receptor. Objective: To determine the effect of comorbid hypertension on the incidence of comorbid cardiovascular disease in Covid-19 patients. Methods: The data used in this study are secondary data by examining data from recaps of patients diagnosed with Covid-19 with heart disease in the isolation treatment room of the NTB Provine Hospital in the period March - December 2020. And analyzing research articles on the effect of hypertension on worsening and a high incidence of comorbid hypertension in Covid-19 patients. Results: The use of anti-hypertensive drugs such as the ACE inhibitor and ARB class of drugs is often associated with the severity of the symptoms of COVID-19, but until now ACE inhibitors and ARBs are still recommended for hypertensive patients because there is no clear evidence that these drugs can aggravate the clinical manifestation of COVID-19 patients. Conclusion: Hypertension is a comorbid that is often found in COVID-19 patients and can worsen the condition of COVID-19 patients. The use of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) can reset ACE2 thereby increasing the susceptibility of cells to viruses.